-
公开(公告)号：US10336798B2
公开(公告)日：2019-07-02
申请号：US15625891
申请日：2017-06-16
申请人： Amgen Inc.
发明人： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC分类号： A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , C07K14/475 , C07K14/495 , C07K14/51 , A61K39/00
摘要： GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20160168223A1
公开(公告)日：2016-06-16
申请号：US15004281
申请日：2016-01-22
申请人： Amgen Inc.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC分类号： C07K14/50
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
摘要翻译： 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
公开(公告)号：US11739131B2
公开(公告)日：2023-08-29
申请号：US16416050
申请日：2019-05-17
申请人： Amgen Inc.
发明人： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Kenneth W. Walker , Bryan Lemon
IPC分类号： C07K14/475 , C07K14/495 , C07K14/51 , A61K38/16 , A61K38/00 , A61K38/18 , A61K38/17 , A61K39/00
CPC分类号： C07K14/475 , A61K38/00 , A61K38/16 , A61K38/17 , A61K38/18 , A61K39/0005 , C07K14/495 , C07K14/51 , A61K2039/6056 , C07K2319/30
摘要： GDF15 polypeptides, constructs comprising GDF15, and mutants thereof are provided. In various embodiments the GDF15 polypeptides, constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US10894814B2
公开(公告)日：2021-01-19
申请号：US15826442
申请日：2017-11-29
申请人： Amgen Inc.
发明人： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Marissa Mock , Kenneth William Walker
IPC分类号： C07K14/475
摘要： Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US20190023757A1
公开(公告)日：2019-01-24
申请号：US15996232
申请日：2018-06-01
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
申请人： Amgen Inc.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
摘要： The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
公开(公告)号：US09822178B2
公开(公告)日：2017-11-21
申请号：US15158178
申请日：2016-05-18
申请人： AMGEN INC.
发明人： Cen Xu , Agnes Eva Hamburger
CPC分类号： C07K16/28 , C07K16/2869 , C07K2317/21 , C07K2317/24 , C07K2317/41 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine.
-
8.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC分类号： C07K14/50 , A61K38/00 , C07K2319/30
摘要： The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
摘要翻译： 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
公开(公告)号：US11248043B2
公开(公告)日：2022-02-15
申请号：US16919032
申请日：2020-07-01
申请人： AMGEN INC.
发明人： Neeraj Jagdish Agrawal , Kevin Graham , Agnes Eva Hamburger , Christopher Mohr , Derek E. Piper , Kenneth William Walker , Zhulun Wang , Cen Xu
IPC分类号： G01N33/53 , A61K39/395 , A61K39/00 , A61K49/00 , A61K49/16 , C07K16/00 , C12P21/08 , C07K16/18 , C07K16/28 , A61P25/06 , A61K38/22 , A61K47/68 , A61K38/17 , A61K51/10 , C07K14/575 , C07K16/26 , C07K14/72 , C07K14/47 , G01N33/74 , G01N33/68
摘要： The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.
-
公开(公告)号：US11072640B2
公开(公告)日：2021-07-27
申请号：US15996232
申请日：2018-06-01
申请人： AMGEN INC.
发明人： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
摘要： The invention provides methods for treating non-alcoholic steatohepatitis (NASH) using FGF21 mutant polypeptides.
-
-
-
-
-
-
-
-
-
搜索结果
26 条记录 (耗时 0.029 秒)
